India approves plans for UNESCO biotech training centre
This article was originally published in Scrip
Executive Summary
India has approved plans to establish UNESCO's (United Nations Educational, Scientific and Cultural Organisation) regional centre for training and education in biotechnology in Faridabad, Haryana. India's cabinet recently approved the proposal, which is being implemented with a budget of Rs995.5 million ($19.8 million). The proposed centre would act as the focal point for co-operation among member countries of the Asian region in biotechnology. It would serve as a regional hub for interdisciplinary education and training in biotechnology with emphasis on novel education programmes relevant to industry, including biotech drug discovery science, nanoscience and medicine, imaging techniques and bioengineering. It is expected to help overcome the shortage of skilled personnel in these areas in India. Collaboration with UNESCO is also expected to open up gateways to international institutions such as the European Molecular Biology Organisation and the International Union of Biochemistry and Molecular Biology, the Indian government added.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet